Substantial progress had been made in the treatment of hepatitis B in the past decade; many safe and effective drugs are now available. However, these drugs suppress but do not eradicate HBV. In addition, these agents may be associated with drug resistance and adverse effects. Hellan Kwon and Anna Lok address important questions regarding the optimization of treatment in patients with hepatitis B.